Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ROIV save search
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Published: 2024-04-02 (Crawled : 11:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 4.79%
H: 3.02%
C: -0.09%
pharma million authorization positive repurchase results study
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 1.2%
H: 0.34%
C: -3.46%
ABUS | News | $2.705 -0.92% 300K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -2.44%
year update financial results
Global Dermatological Drugs Market Set to Surpass US$30 Billion with Advanced Nanotechnology and Aging Population Fostering Growth
Published: 2024-02-28 (Crawled : 11:00) - prnewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -0.76%
H: 0.51%
C: 0.0%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: 0.05%
H: 0.06%
C: -0.95%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.6%
H: 0.02%
C: -1.03%
global set dermatological advanced growth market
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: -0.64%
business update financial results
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 0.78%
H: 0.97%
C: -2.91%
report business update financial results
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 4.52%
H: 2.02%
C: 1.25%
IMVT 4 | $27.7 -2.19% 260K
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
Published: 2023-12-14 (Crawled : 14:30) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 2.22%
H: 1.27%
C: 0.72%
rvt-3101 disease antibody treatment acquisition roche
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -0.11%
H: 0.66%
C: 0.0%
IMVT 4 | $27.7 -2.19% 260K
|
Health Technology
|
| O: 2.92%
H: 6.63%
C: 4.32%
imvt-1402 positive potential results
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -3.29%
H: 3.34%
C: 3.06%
lupus results study phase 2
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -1.93%
H: 5.79%
C: 4.75%
business update financial results
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 0.58%
H: 2.79%
C: 2.44%
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 0.56%
H: 2.68%
C: 1.68%
ABUS | News | $2.705 -0.92% 300K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
update financial results
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
Published: 2023-10-30 (Crawled : 22:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -1.18%
H: 4.49%
C: 3.47%
report business update financial results
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
Published: 2023-10-23 (Crawled : 05:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 3.83%
H: 0.0%
C: -14.31%
rvt-3101 disease antibody treatment acquire roche agreement
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Published: 2023-10-23 (Crawled : 05:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 3.83%
H: 0.0%
C: -14.31%
rvt-3101 announcement disease antibody treatment acquire roche agreement
Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -1.0%
H: 1.15%
C: 0.1%
trial
Immunovant Announces Proposed Offering of $300 Million of Common Stock
Published: 2023-09-26 (Crawled : 21:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 2.9%
H: 3.6%
C: 3.29%
IMVT 4 | $27.7 -2.19% 260K
|
Health Technology
|
| O: 6.36%
H: 3.98%
C: -7.02%
offering
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Published: 2023-09-26 (Crawled : 10:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 15.57%
H: 8.73%
C: 5.17%
IMVT 4 | $27.7 -2.19% 260K
|
Health Technology
|
| O: 59.22%
H: 29.2%
C: 23.75%
imvt-1402 positive results
Roivant Announces Completion of Redemption of its Outstanding Warrants
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: 0.4%
H: 1.5%
C: -9.01%
redemption
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
Published: 2023-08-17 (Crawled : 20:00) - globenewswire.com
ROIV | $10.38 0.19% 810K
|
Manufacturing
|
| O: -0.96%
H: 6.08%
C: 4.82%
redemption market
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.